INAB / 11 Insiders Tip More Capital into IN8BIO and Broker HC Wainwright Initiates With Bullish $14 Target

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta more_horizontal

IN8bio, Inc. (INAB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INAB's 50-day more_horizontal

Does IN8bio, Inc. (INAB) have what it takes to be a top stock pick for momentum investors? Let's find out. more_horizontal

Penny stocks to watch as bank stocks fall in the stock market today. The post Stock Market Today: Penny Stocks To Watch Amid Banking Crisis appeared f more_horizontal

IN8bio (NASDAQ: INAB ) stock is rising higher on Wednesday as the company's shares continue their wild swings this week. The strong movement for the s more_horizontal

IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan more_horizontal

In8bio (NASDAQ: INAB ) stock is on the move Tuesday as investors react to a recent rally and additional news from the biotechnology company. First off more_horizontal

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innova more_horizontal